Undisclosed Pfizer-selected oncology target 1

Undisclosed Pfizer-selected oncology target 1 refers to the first therapeutic target selected by Pfizer under its 2016 strategic research collaboration and license agreement with BioInvent International AB. Discovered using BioInvent's proprietary F.I.R.S.T™ platform, the target is a protein expressed on tumor-associated myeloid cells (TAMs), which are known to create an immunosuppressive environment that facilitates tumor growth and evasion of the immune system. Drugs targeting this molecule, typically monoclonal antibodies, are designed to either reverse the immunosuppressive activity of these myeloid cells or reduce their population within the tumor microenvironment. By modulating the myeloid compartment, these therapies aim to enhance the anti-tumor immune response and potentially overcome resistance to existing checkpoint inhibitors. While the specific molecular identity of the target remains undisclosed in public filings, it represents a novel approach in immuno-oncology focusing on the innate immune system's role in cancer progression.

Other names

Pfizer-selected oncology target 1BioInvent-Pfizer target 1